ASH 2020 | SIERRA: Iomab-B for pre-HSCT AML

Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the prospective Phase III SIERRA trial (NCT02665065) of targeted radiotherapy with iomab-B, an anti-CD45 monoclonal antibody, in relapsed/refractory acute myeloid leukemia (AML). The trial was designed to reduce the toxicity associated with conditioning in a patient population who are too unfit to withstand high dose myeloablative pre-conditioning. The ongoing trial randomized patients to receive either iomab-B or conventional care. Personalized therapeutic doses were established that would treat active disease in the bone marrow while limiting the radiation dose reaching the liver to 24 Gray. The analysis shows that the personalized doses allowed for reliable engraftment after transplant in all cases. Additionally, results from patients treated to date show that iomab-B treatment caused low rates of severe mucositis, febrile neutropenia and sepsis. The occurrence of these adverse events was not correlated to the administered dose of iomab-B or the dose delivered to the bone marrow. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.